Amgen has announced the appointment of Wanda M. Austin to its Board of Directors, effective upon the December Board and committee meetings.
Dr. Austin will serve as a member of the Board’s Audit Committee and the Corporate Responsibility and Compliance Committee. Following the appointment of Dr. Austin, the Board will comprise 14 directors, 13 of whom are independent.
“We are pleased to welcome Dr. Wanda Austin to Amgen’s Board,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “Wanda’s deep experience in long-cycle technology and engineering settings and her senior leadership experience will be invaluable to Amgen.”
Dr. Austin, 63, is the retired president and chief executive officer of The Aerospace Corporation, a leading architect of the United States’ national security space programs, where she served from 2008 until her retirement in 2016. From 2004 to 2007, Dr. Austin was senior vice president, National Systems Group of The Aerospace Corporation. Dr. Austin joined The Aerospace Corporation in 1979 and served in various positions from 1979 until 2004.
Dr. Austin has served as an Adjunct Research Professor at the University of Southern California’s Viterbi School of Engineering since 2007. She is the co-founder of MakingSpace, where she serves as a motivational speaker on STEM education.
Dr. Austin has been a director of Chevron Corporation, a petroleum, exploration, production and refining company, since 2016. She is a trustee of the University of Southern California and previously served on the boards of directors of the National Geographic Society and the Space Foundation.
Dr. Austin received an undergraduate degree from Franklin & Marshall College, a master’s degree from the University of Pittsburgh and a doctorate from the University of Southern California.
The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.
Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.
Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.